ResearcherNanjing Drum Tower HospitalNo recent work listed

Wan Feng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6538-6931; OpenAlex author ID A5102863733. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper

Papers 2

Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. Co-author DOI 10.1016/j.biopha.2015.08.017 ↗
Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.02.012 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Bin Zhang · 2 shared papers, 2014–2015 · strength 0.13
- Paper Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cycli… DOI 10.1016/j.biopha.2015.08.017 ↗
- Paper Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. DOI 10.1016/j.canlet.2014.02.012 ↗
Xiaoping Zou · 2 shared papers, 2014–2015 · strength 0.13
- Paper Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cycli… DOI 10.1016/j.biopha.2015.08.017 ↗
- Paper Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. DOI 10.1016/j.canlet.2014.02.012 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.